#USA #New York #securities lawsuit #Shareholder Rights #Unicycive Therapeutics

Shareholder Alert: Class Action Against Unicycive Therapeutics

In a significant development in the financial world, investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) are being called to action regarding a class action lawsuit that highlights critical concerns concerning the company's compliance with federal regulations and their disclosures to shareholders. This lawsuit has emerged in the wake of the company's recent announcements regarding their product, oxylanthanum carbonate (OLC), and its awaited FDA approval.

The Allegations

The class action lawsuit, backed by the prominent law firm SueWallSt, asserts that from December 29, 2025, to June 29, 2026, Unicycive made several assurances to its shareholders. The company conveyed confidence that a regulatory decision regarding OLC would be forthcoming by June 29, 2026. They also indicated that a commercial launch was expected “later this year.” However, reports have surfaced indicating that Unicycive purportedly failed to conduct necessary inspections of its third-party manufacturing facility, which had already caused prior complications, including the issuance of a Complete Response Letter from the FDA in June 2025.

A Timeline of Misinformation

On June 29, 2026, shares of UNCY closed at $7.70, reflecting the optimistic projections made by the company. However, just one day later, after announcing a second Complete Response Letter to the FDA due to unresolved manufacturing deficiencies, shares plummeted dramatically to $4.69—a staggering decline of over 39% in a single trading session. This downward trend accentuates the anxiety surrounding Unicycive's operational capabilities and transparency with investors.

The stark contrast between what was promised and what ultimately transpired has spurred many shareholders to evaluate their legal options. The lawsuit specifically accuses Unicycive of making misleading statements regarding the compliance status of its manufacturing partner and their readiness for product launch, thereby misguiding investors into supporting inflated stock prices.

Financial Snapshot

A key component of this case involves Unicycive's financial disclosures. While the company projected a cash position of $41.3 million in May 2026, indicating sufficient funds to navigate the approval process late into 2027, the reality of their situation has shifted dramatically with the new regulatory challenges. Furthermore, it has been alleged that Unicycive did not verify whether their manufacturer had resolved previously cited deficiencies, pointing to potential negligence on the company's part regarding proper oversight.

Seeking Accountability

Investors who purchased shares within the specified period may be eligible to partake in the lawsuit, leading to possible compensation for losses incurred due to the drastic share price decline following these revelations. SueWallSt has indicated that interested parties should act swiftly if they wish to pursue recovery of their investments.

Important Dates and Next Steps

The deadline for investors to apply as lead plaintiffs in this class action is set for November 2, 2026. This appointment is critical as it ensures that the most affected shareholders have a voice in the proceedings. Those who participated in purchasing UNCY shares during this period and subsequently sold at a loss may still qualify for compensation, indicating how expansive the eligibility criteria are for this legal pursuit.

For investors similar to you, gathering brokerage records that detail purchase dates, quantities, and prices becomes vital for determining eligibility. SueWallSt invites any affected shareholders to submit their information to assess potential recovery avenues without any upfront costs. Once involved in this legal trajectory, plaintiffs typically face no financial burden unless the case resolves favorably.

Conclusion

In summary, the situation surrounding Unicycive Therapeutics presents a cautionary tale for investors regarding the need for transparency and accountability from companies. With the class action lawsuit underway, shareholders are encouraged to stay informed and proactive, as collective action could lead to justice and potential restitution. For further inquiries, stakeholders are urged to reach out directly to Joseph E. Levi, Esq., of Levi Korsinsky, LLP, who emphasizes that accountability is paramount in today’s complex financial landscape.